These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31790636)

  • 1. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
    Sarno F; Nebbioso A; Altucci L
    Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
    Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
    J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
    Stein EM; Tallman MS
    Curr Opin Hematol; 2015 Mar; 22(2):92-6. PubMed ID: 25635757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
    Marcos-Villar L; Nieto A
    Sci Rep; 2019 Nov; 9(1):16862. PubMed ID: 31727944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
    Waters NJ
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):891-901. PubMed ID: 28229434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
    Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
    Stein EM; Garcia-Manero G; Rizzieri DA; Tibes R; Berdeja JG; Savona MR; Jongen-Lavrenic M; Altman JK; Thomson B; Blakemore SJ; Daigle SR; Waters NJ; Suttle AB; Clawson A; Pollock R; Krivtsov A; Armstrong SA; DiMartino J; Hedrick E; Löwenberg B; Tallman MS
    Blood; 2018 Jun; 131(24):2661-2669. PubMed ID: 29724899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
    Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
    Wong M; Polly P; Liu T
    Am J Cancer Res; 2015; 5(9):2823-37. PubMed ID: 26609488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
    Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
    Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia.
    Cao M; Li T; Chen Y; Zhai X
    Mini Rev Med Chem; 2021; 21(11):1337-1350. PubMed ID: 33430727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
    Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
    Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
    Chen J; Park HJ
    ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
    Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
    Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
    Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
    Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.